학술논문
646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S454-S455
Subject
Language
ISSN
0923-7534